Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoembolization with epirubicin-loaded CalliSpheres microspheres for hepatocellular carcinoma
ChiCTR2000036221Phase 4Recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jul 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epirubicin in hepatocellular carcinoma (HCC), sponsored by Shenzhen Second People's Hospital. Primary endpoints: progression-free survival, serious adverse events and 2 more. Started Jul 2020; status: recruiting.
02
Drugs
epirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000036221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036221.